О влиянии лекарственных препаратов на одышку

1. O'Driscoll М., Corner Bailey С. The experience of breathlessness in lung cancer. Eur. J. Cancer Care 1999; 8 (1): 37-43.

2. Anto J. М., Vermeire P., Sunyer J. Chronic obstructive pulmonary disease. Respiratory epidemiology in Europe. Eur. Respir. Monograph 2000; 5; 1-23.

3. Lynn J., Ely E.W ., Zhong Z. et al. Living and dying with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2000; 48 (5, suppl.): 91-100.

4. Luce J.M., Luce J.A. Perspectives on care at the close of life. Management of dyspnea in patients with far-advanced lung disease: "once I lose it, it's kind of hard to catch it... ". J.A.M.A. 2001; 285 (10): 1331-1337.

5. Вотчал Б. E., Магазаник И. А. Современные представления об одышке. Клин. мед. 1966; 3: 15-17.

6. Comroe J.H. Some theories of me mechanism of dyspnea. In: Howell J.B.L., Campbell E.J.M., eds. Breathlessness. Philadelphia: FA Davis, 1966. 1-7.

7. Сенкевич Н.Ю. Качество жизни при хронической обструктивной болезни легких. В кн.: Чучалин А.Г. (ред.) Хронические обструктивные болезни легких. М.: ЗАО Изд-во "Бином"; 1998. 171-189.

8. Siafakas N. М., Schiza S., Xirouhaki N., Bouros D. Is dyspnoea the main determinant of quality of life in the failing lung? A review. Eur. Respir. Rev. 1997; 7 (42): 53-56.

9. Knuiman M .W ., James A.L., Divitini M.L. et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann. Epidemiol. 1999; 9 (5): 297-306.

10. Stark R.D. Dyspnoea: assessment and pharmacological manipulation. Eur. Respir. Rev. 1988; 1: 280-287.

11. Jones G.L., Killian K.J., Summers E. et al. Inspiratory muscle forces and endurance in maximum resistive loading. J. Appl. Physiol. 1985; 58: 1608-1615.

12. Burdon J.G.W., Juniper E.F., Killian K.J. et al. The perception of breathlessness in asthma. Am. Rev. Respir. Dis. 1982; 126: 825-828.

13. Stark R.D., Gambles S.A., Chatterjee S.S. An exercise test to assess clinical dyspnoea; estimation of reproducibility and sensitivity. Br. J. Dis. Chest 1982; 76: 269-278.

14. Stark R.D., Gambles S.A. Effects of salbutamol, ipratropium bromide and disodium cromoglycate on breathlessness induced by exercise in normal subjects. Br. J. Clin. Pharmacol. 1981; 12: 497-501.

15. Wolkove N., Dajczman E., Colacone A., Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.

16. Misuri G., Mancini М., Iandelli I. et al. Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma: protective effects of fenoterol. Pulm. Pharmacol. Ther. 1997; 10 (5—6): 299-304.

17. Poole P.J., Brodie S.М., Stewart J.M., Black P.N. The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med. 1998; 28 (3): 322-326.

18. Taube C., Lehnigk B., Paasch K. et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162 (1): 216-220.

19. Weiner P., Magadle R., Berar-Yanay N. et al. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest 2000; 118 (3): 672-678.

20. Dullinger D., Kronenberg R., Niewoehner D.E. Efficacy of inhaled metaproterenoi and orally administered theophylline in patients with chronic airflow obstruction. Ibid. 1986; 89: 171-173.

21. Papiris S., Galavotti V., Sturani C. Effects of beta-agonists on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Respiration 1986; 49: 101-108.

22. Guyatt G.H., Townsend М., Pugsley S.O. et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.

23. Calverley P.M.A. Pharmacotherapy and quality of life. Eur. Respir. Rev. 1997; 42: 96-99.

24. Rennard S.I. Anticholinergics and B-agonists: efficacy, safety and combination therapy in chronic obstructive pulmonary disease. In: Barns P.J., Buist A.S., eds. The role of anticholinergics in chronic obstructive pulmonary disease chronic asthma. 1997. 137-144.

25. Шварц Г.Я., Цой А.Н. Антихолинергические средства в лечении больных хронической обструктивной болезнью легких. В кн.: Чучалин А.Г. (ред.) Хроническая обструктивная болезнь легких. М.; 1998. 234-249.

26. Noseda A., Carpiaux J.P., Schmerber J. et al. How do patients with either asthma and COPD perceive acute bronchodilatation? Eur. Respir. J. 1993; 6: 636-644.

27. Krai B., Parakova Z ., Tilser P. Perception of dyspnea in astmatics-long-term study. Vnitr-Lek. 1995; 41 (12): 810-815.

28. Hay J.G., Stone P., Carter J. et al. Bronchodilatator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. 1992; 5: 659-664.

29. Calverley P.M.A. Pharmacology of bronchodilators used in obstructive airways disease. In: Barns P.J., Buist A.S., eds. The role of anticholinergics in chronic obstructive pulmonary disease chronic asthma. 1997; 72-90.

30. O'Donnell A.E., Lam М., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 1998; 158: 1557-1565.

31. O'Donnell A.E., Lam М., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Ibid. 1999; 160: 542-549.

32. O'Donnell A.E., Webb KA. Exertional breathlessness in patients with chronic airflow limitation. Am. Rev. Respir. Dis. 1993; 148: 1351-1357.

33. Aldrich Т.К., Hendler J.M., Vizioli L.D. et al. Intrinsic positive end-expiratory pressure in ambulatory patients with airways obstruction. Ibid. 147: 845-849.

34. Hatipoglu U., Laghi F., Tobin M.J. Does inhaled albuterol improve diaphragmatic contractility in patients patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1916-1921.

35. Boni E., Corda L., Damiani G. P. et al. Volume effect and exertional dyspnea after bronchodilator in COPD patients with and without expiratory flow limitation. In: European Respiratory Society. Annual congress. Geneva; 1998. N P1079.

36. Teramoto S., Suzuki М., Matsuse T. et al. [The effect of inhaled anticholinergic drug on dyspnea and on the physiologic function of respiratory system in patients with chronic obstructive pulmonary disease]. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35 (11): 1209-1214.

37. Burdon J.G.W., Pain M.C.F., Rubinfeld A.R., Nana A. Chronic lung disease and the perception of breathlessness: a clinical perspective. Eur. Respir. J. 1994; 7: 1342-1349.

38. Абросимов B.H., Бяловский Ю.Ю. Способ использования Ипратропиум бромида с целью повышения устойчивости к дополнительному респираторному сопротивлению. Описание изобретения к патенту Российской Федерации RU 2108091 С1. 10. 04. 98.

39. Blosser S.A., Maxwell S.L., Reeves-Hoche М.К. et al. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995; 108 (3): 730-735.

40. Patakas D., Andreadis D., M avrofridis E., Argyropoulou P. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir. Med. 1998; 92 (9): 1116-1121.

41. Ram irez-Venegas A., Ward J., Lentine Т., Mahler D.A. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112 (2): 336-340.

42. Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Ibid. 1999; 116 (4): 1137-1138.

43. Ashutosh K., Dev G., Steele D. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. Ibid. 1995; 107 (1): 173-178.

44. Colice G.L. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (1A): 11-18.

45. Murciano D., Aubier М., Lecocguic Y., Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N. Engl. J. Med. 1984; 311: 349-353.

46. Alexander M.R., Dull W.L., Kasik J.E. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. J.A.M.A. 1980; 244: 2286-2290.

47. Eaton M.L., McDonald F.M., Church T.R., Niewoehner D.E. Effects of theophylline on breathlessness in patients with chronic airflow obstruction. Chest 1982; 82: 538-542.

48. Mahler D.A., Matthay R.A., Snyder P.E. et al. Sustainedrelease theophylline reduces dyspnea in non-reversible obstructive airway disease. Am. Rev. Respir. Dis. 1985; 131: 22-25.

49. Murciano D., Auclair M.-H., Pariente R., Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N. Engl. J. Med. 1989; 320: 1521-1525.

50. Anthonisen N.R., Benn V., Glenn F. et al. Trial of theophylline therapy in stable COPD. Am. Rev. Respir. Dis. 1991; 143: A446.

51. O'Neill P.A., Stark R.D., Morton P.B. Do prostaglandins have a role in breathlessness? Ibid. 1985; 132: 22-24.

52. O'Neill P.A., Stretton T.B., Stark R.D., Ellis S.H. The effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung. Br. J. Dis. Chest 1986; 80: 72-79.

53. Волкова Л.И., Букреева E.Б., Боярко В.В., Польща Н.Г. Опыт применения фенспирида при обострении хронического бронхита. Клин, фармакол. и тер. 2000; 9 (5): 10-12.

54. Guz A. Effects of blocking the vagus nerves in man. In: Howell J.B.L., Campbell E.J.M., eds. Breathlessness. Oxford: Blackwell; 1966. 35-40.

55. Noble M.I.M., Eisele J.H., Trenchard D., Guz A. Effect of selective peripheral nerve blocks on respiratory sensations. In: Porter R., ed. Breathing: Hering-Breuer Centenary Symposium,. London: Churchill; 1970. 233-246.

56. Stark R.D., O'Neill P.A., Russell N.J.W. et al. Effects of smallparticle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin. Sei. 1985; 69: 29-36.

57. Paintal A.C. Mechanisms of stimulation of type J pulmonary receptors. J. Physiol. (Lond.) 1969; 203: 511-532.

58. Paintal A.C. Thoracic receptors connected with sensation. Br. Med. Bull. 1977; 33: 169-174.

59. Howard P., Cayton R.M ., Brennan S .R., Anderson P.B. Lignocaine aerosol and persistent cough. Br. J. Dis. Chest 1977; 71: 19-24.

60. Guz A., Noble M.I.M., Eisele J.H., Trenchard D. Experimental results of vagal block in cardiopulmonary disease. In: Porter R., ed. Breathing: Hering-Breuer Centenary Symposium. London: Churchill; 1970. 315-328.

61. Guz A., Hamilton R.D., Winning A.J. The effects of local anaesthetic aerosols of different particle size on the response to C02 rebreathing in man. J. Physiol. (Lond.) 1985; 358: 94.

62. Hamilton R.D., Winning A.J., Guz A. Maximal exercise in normal man — effect of inhaled local anaesthetic aerosol depositing at alveolar level. Clin. Sei. 1985; 68: 46.

63. Stark R.D., Gambles S.A., Morton P.B., Sharm an P. The effects of codeine on respiratory sensations during exercise in healthy subjects. Ibid. 1982; 63: 53.

64. Robin E.D., Burk C.M. Single-patient randomized clinical trial: opiates for intractable dyspnea. Chest 1986; 90: 888-892.

65. Woodcock A.A., Gross E.R., Geliert A. et al. Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N. Engl. J. Med. 1981; 305: 1611-1616.

66. Rise K.L. Treatment of dyspnea with psychotropic agents. Chest 1986; 90 (6): 789-790.

67. Light R.W ., Muro J.R., Sato R.I. et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1989; 139: 126-133.

68. Altose M.D. Management of breathlessness. In: Jones L.M., Killian J.K., eds. Breathlessness. The Campbell Symposium. Ontario; 1992. 161-169.

69. Tanaka K., Shima Y., Kakinuma R. et al. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn. J. Clin. Oncol. 1999; 29 (12): 600-603.

70. Mazzocato C., Buclin T., Rapin C.H. The effects of morphine on dyspnea and ventilatory function in elderly patients with dvanced cancer: a randomized double-blind controlled trial. Ann. Oncol. 1999; 10 (12): 1511-1514.

71. Mitchell-Heggs P., Murphy K., Minty K. et al. Diazepam in the treatment of dyspnea in the "pink puffer" syndrome. Quart. J. Med. 1980; 193: 9-20.

72. Woodcock A.A., Gross E.R., Geddes D.M. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br. Med. J. (Clin. Res.) 1981; 282: 343-346.

73. Man G.C.W., Hsu K., Sproule B. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 832-836.

74. O'Neill P.A., Morton P.B., Stark R.D. Chlorpromazine — a specific effect on breathlessness? Br. J. Clin. Pharmacol. 1985; 19: 793-797.

75. Woodcock A.A., Johnson M.A., Geddes D.M. Breathlessness, alcohol and opiates. N. Engl. J. Med. 1982; 306: 1363-1364.

76. Burki N.K. Dyspnea. Lung 1987; 165: 269-277.